WA Therapeutics Accelerator - From Bench to Batch: pre-empting the needs for commercial production of therapeutics
Description
From Bench to Batch: pre-empting the needs for commercial production of therapeutics
WA Therapeutics Accelerator (WATA) Case Study 2
Friday 11 December 2026, 9:00am to 12:00pm
Bentley Technology Park Hub and BioCina.
A promising compound is only the start. Before a therapy reaches patients, someone has to make it reliably, at scale and to regulatory standards. Investors and partners will ask how you plan to do that, often earlier than researchers expect.
This WATA session covers the scientific, technical and operational challenges of moving from laboratory discovery to commercial manufacturing, and the choices you can make now to avoid costly delays later.
You will hear about:
• what a contract development and manufacturing organisation (CDMO) does, and chemistry, manufacturing and controls (CMC) in plain terms
• the issues that most often slow down or derail technology transfer, and how to avoid them at discovery
• what to consider for small molecules, nucleotides and biologics
• tools that carry through from the research lab to commercial scale, how early to adopt them, and the IP and freedom-to-operate questions to ask
• a panel reality check on cost, timelines and Australia's manufacturing track record
Speakers include Brett Alderson from BioCina, Dr Nicolas Pichon from Cytiva, Dr Samantha South from Patrys and Dr James Williams, CEO - HTG. The morning includes time to network with speakers and other researchers over morning tea, and finishes with a small-group tour of BioCina's manufacturing facility.
Who should attend: WA researchers developing therapeutics, research commercialisation staff and early career researchers. Projects registered with WATA are strongly encouraged to attend.
BioCina tour places are limited. Registrations close Friday 4 December 2026, or earlier if places fill. Closed shoes are required for the tour.
Free to attend.
Hosted by HTG with Curtin University and BioCina. WATA is run by Health Translation Group Limited (HTG) and funded by the WA Government's Innovation Pathways Program, from the New Industries and Innovation Fund, through the Department of Energy and Economic Diversification.
Agenda
- 8:45 am - 9:00 am
Arrival and Registration
- 9:00 am - 10:30 am
Manufacturing Case Studies
This WATA session covers the scientific, technical and operational challenges of moving from laboratory discovery to commercial manufacturing, and the choices you can make now to avoid costly delays later. You will hear about: • what a contract development and manufacturing organisation (CDMO) does, and chemistry, manufacturing and controls (CMC) in plain terms • the issues that most often slow down or derail technology transfer, and how to avoid them at discovery • what to consider for small molecules, nucleotides and biologics • tools that carry through from the research lab to commercial scale, how early to adopt them, and the IP and freedom-to-operate questions to ask • a panel reality check on cost, timelines and Australia's manufacturing track record
- 10:30 am - 11:00 am
Morning Tea Provided
- 11:00 am - 11:10 am
Walk to BioCina
- 11:10 am - 12:00 pm
BioCina Tour - Small Groups
Places are limited. Tour numbers are capped. Registrations close Friday 4 December 2026, or earlier if places fill. Closed shoes are required for the tour.
Tickets for good, not greed Humanitix dedicates 100% of profits from booking fees to charity



